StreetInsider.com News Articles

Form 4 Axogen, Inc. For: Feb 26 Filed by: Kemp Jens

Mon, 02 Mar 2026 18:17:00 -0500

si-local-file:///var/storage/secattach/20260302/26094357.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: Kemp Jens

Mon, 02 Mar 2026 18:17:00 -0500

si-local-file:///var/storage/secattach/20260302/26094357.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: Began Marc A

Mon, 02 Mar 2026 18:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26094353.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: Began Marc A

Mon, 02 Mar 2026 18:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26094353.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: DeVinney Erick Wayne

Mon, 02 Mar 2026 18:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26094356.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: DeVinney Erick Wayne

Mon, 02 Mar 2026 18:16:00 -0500

si-local-file:///var/storage/secattach/20260302/26094356.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: Hartley Lindsey Marie

Fri, 27 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260227/26082150.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: Hartley Lindsey Marie

Fri, 27 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260227/26082150.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: DALE MICHAEL D

Fri, 27 Feb 2026 16:23:00 -0500

si-local-file:///var/storage/secattach/20260227/26082052.html

Form 4 Axogen, Inc. For: Feb 26 Filed by: DALE MICHAEL D

Fri, 27 Feb 2026 16:23:00 -0500

si-local-file:///var/storage/secattach/20260227/26082052.html

AxoGen (AXGN) Reiterated at Market Outperform by Citizens After a Strong Quarter

Wed, 25 Feb 2026 05:05:03 -0500

Citizens analyst David Turkaly reiterated a Market Outperform rating and $42.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

The analyst commented, "AXGN's quarterly revenue of $59.9 mln (+21.3% y/y) was in line with its January preannouncement; recall, this figure checked in ~3% above the Street at that time. Operationally, it was a strong quarter for the company, with momentum across its four target markets (Extremities, Breast, OMF/ H&N, and Prostate), with more to come in 2026 on the surgeon education and data-generation fronts. Quarterly results reflected an aggregate ~$9.1 mln hit (~$1.9 mln to COGS and $7.2 mln of non-cash stock

Form 4 Axogen, Inc. For: Feb 22 Filed by: Hartley Lindsey Marie

Tue, 24 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260224/26052025.html

Form 4 Axogen, Inc. For: Feb 22 Filed by: Hartley Lindsey Marie

Tue, 24 Feb 2026 16:26:00 -0500

si-local-file:///var/storage/secattach/20260224/26052025.html

Form 10-K Axogen, Inc. For: Dec 31

Tue, 24 Feb 2026 16:24:00 -0500

si-local-file:///var/storage/secattach/20260224/26051971.html

Form 10-K Axogen, Inc. For: Dec 31

Tue, 24 Feb 2026 16:24:00 -0500

si-local-file:///var/storage/secattach/20260224/26051971.html

AxoGen (AXGN) Tops Q4 EPS by 1c

Tue, 24 Feb 2026 08:06:44 -0500

AxoGen (NASDAQ: AXGN) reported Q4 EPS of $0.07, $0.01 better than the analyst estimate of $0.06. Revenue for the quarter came in at $59.9 million versus the consensus estimate of $58.25 million.

For earnings history and earnings-related data on AxoGen (AXGN) click here.

Form 8-K Axogen, Inc. For: Feb 24

Tue, 24 Feb 2026 07:02:00 -0500

si-local-file:///var/storage/secattach/20260224/26046540.html

Form 8-K Axogen, Inc. For: Feb 24

Tue, 24 Feb 2026 07:02:00 -0500

si-local-file:///var/storage/secattach/20260224/26046540.html

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

Tue, 24 Feb 2026 07:00:00 -0500

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025.

Fourth Quarter Financial Results

Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue.

Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the

Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results

Tue, 24 Feb 2026 07:00:00 -0500

Fourth Quarter Financial Results

Fourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue.

Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the

AxoGen, Inc. (AXGN) PT Raised to $42 at Citizens

Tue, 24 Feb 2026 04:08:20 -0500

Citizens analyst David Turkaly raised the price target on AxoGen, Inc. (NASDAQ: AXGN) to $42.00 (from $34.00) while maintaining a Market Underperform rating.

Wells Fargo Starts AxoGen, Inc. (AXGN) at Overweight

Thu, 19 Feb 2026 05:45:46 -0500

Wells Fargo analyst Larry Biegelsen initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Overweight rating and a price target of $40.00.

The analyst comments: "AXGN is the only company fully focused on the treatment of peripheral nerve injuries. Its lead product, Avance, is an off‑the‑shelf biologic nerve graft that supports regeneration without harvesting a patient’s own nerve, unlike autograft, which is the gold standard in nerve repair. Avance has no direct biologic competitor in the market or in development, providing a clear first‑mover advantage. The opportunity for Avance reflects both (1) share gains from autograft and (2) market growth, as

Wells Fargo Starts AxoGen, Inc. (AXGN) at Overweight

Thu, 19 Feb 2026 05:45:46 -0500

Wells Fargo analyst Larry Biegelsen initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Overweight rating and a price target of $40.00.

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Tue, 17 Feb 2026 07:00:00 -0500

ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Raymond James 47th Annual Institutional Investors Conference
Participation: Presentation and 1x1 investor meetings
Date/Time: Presentation Tuesday, March 3, 2026, 3:25 PM ET
Webcast Link: Raymond James/Axogen Presentation

Leerink Global Healthcare Conference
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ET

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Tue, 17 Feb 2026 07:00:00 -0500

Leerink Global Healthcare Conference
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Monday, March 9, 2026, 1:00 PM ET